Sophie Henderson, Senior Strategic Consultant at CluePoints, said: “This year we have seen risk-based quality management (RBQM) take center stage in clinical research. ICH E6(R3) emphasized the importance of flexibility, critical thinking and quality-by-design. With regulatory backing and increasing adoption, the industry is learning more about how RBQM can unlock value for drug development and sponsor organizations.”